Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository
March 13 2018 - 5:00AM
Business Wire
Abzena plc, the life sciences group providing services and
technologies to enable the discovery, design, development and
manufacture of biopharmaceutical products, has signed an agreement
to access a major cell line depository.
The agreement with an unnamed institution will allow Abzena
access to cell lines representing multiple different species,
tissue types and genetic disorders. This removes the lengthy
process of negotiating individual cell line licences for Abzena and
its customers.
The positive impact for customers will be a more streamlined
development of specialised bioassays. It will be able to provide
faster, more comprehensive and more efficient functional
characterisation, lead selection and potency assay development for
its customers’ novel biologic drug candidates.
Dr. Campbell Bunce, SVP, Scientific Operations,
commented:
“Securing access to this cell bank will be a major benefit to
both us and our customers. We will be able to offer broader
capabilities for evaluating and testing our customers’ drug
candidates to help advance the next generation of
biopharmaceuticals.”
-Ends-
About Abzena
Abzena provides proprietary technologies and complementary
services to enable the development and manufacture of
biopharmaceutical products.
The term ‘ABZENA Inside’ is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena
has the potential to earn future licence fees, milestone payments
and/or royalties on ‘ABZENA Inside’ products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, and Bristol,
Pennsylvania:
- Biology research studies, including
immunogenicity assessment of candidate biopharmaceutical products
and bioassay development
- Protein engineering to create humanized
antibodies and deimmunised therapeutic proteins
- Cell line development for the
manufacture of recombinant proteins and antibodies
- Contract process development and GMP
manufacture of biopharmaceuticals, including monoclonal antibodies
and recombinant proteins for preclinical and clinical studies
- Contract synthetic chemistry and
bioconjugation research services, focused on antibody-drug
conjugates
- Proprietary site-specific conjugation
technologies and novel payloads for ADC development
- GMP manufacturer of ADC linkers,
payloads & combined linker-payloads
- GMP analytical services for
biopharmaceutical manufacturing projects
For more information, visit www.abzena.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180313005183/en/
Abzena plcJohn Burt, CEOCampbell Bunce, SVP, Scientific
OperationsMin Park, Global Head of MarketingJoseph Reeds, Marketing
Manager+441223903498min.park@abzena.comorInstinctif
PartnersMelanie Toyne
Sewell+442074572020abzena@instinctif.com
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024